1. Launch of Brevagen 2. Announcement of next assertion suit (basically a lawsuit against multiple infringers) 3. Approval in Europe and Pac Rim for Brevagen 4. Licensing deals for the use of non-coding DNA 5. Info relating to collaboration of cancer product with one of world's largest pharmaceutical cos. 6. More patents surrounding DNA 7. Update on RareCellect their global prenatal testing product ($2b a year mkt) 8. Year end numbers (6/30/11 is their yr end) 9. Follow on cancer products (Ovarian, colerrectal, uterine)
While the company wont give specifics regarding their licensing deal, I would be willing to bet new deals include royalties on products generated from the non-coding DNA database.
I wouldnt be surprised to see another collaboration with a major player. In the last few months research is proving that "junk DNA" is where we will find the cures to many diseases.
Because Genetic Technologies, with their intellectual property, controls access to 95% of DNA of every creature on earth, it makes sense that this company should be viewed as a VERY LIKELY acquisition candidate. I think it's safe to say that this database is worth tens if not hundreds of billions of dollars. So I wouldnt sweat the day to day fluctuations of the share price.